<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476019</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 463588-CS2</org_study_id>
    <nct_id>NCT02476019</nct_id>
    <nct_alias>NCT02463240</nct_alias>
  </id_info>
  <brief_title>A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients</brief_title>
  <acronym>FGFR4-CS2</acronym>
  <official_title>A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 (ISIS-FGFR4RX, an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4) Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of ISIS-FGFR4RX.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Energy Expenditure using both room calorimetry and hood (metabolic cart) calorimetry</measure>
    <time_frame>From baseline to the average of weeks 14 and 16</time_frame>
    <description>As measured by:
Resting Metabolic rate (kcal/min)
Resting metabolic rate adjusted for changes in body composition (kcal/min)
Resting fat oxidation (grams/24 hr)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability will be assessed by determining the incidence, and severity of adverse effects and changes in laboratory evaluations within each treatment group.</measure>
    <time_frame>33 weeks</time_frame>
    <description>Safety results in patients dosed with ISIS 463588 will be compared with those from patients dosed with placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>ISIS-FGFR4RX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISIS-FGFR4RX administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS-FGFR4RX</intervention_name>
    <description>ISIS-FGFR4RX administered subcutaneously</description>
    <arm_group_label>ISIS-FGFR4RX</arm_group_label>
    <other_name>ISIS 463588</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law and be able to comply with all study requirements

          2. Male or female patients between the age of 18-65 years, inclusive

               -  Females: Must be post-menopausal (defined as 12 months of spontaneous amenorrhea
                  in females &gt; 55 years of age or, in females â‰¤ 55 years, 12 months of spontaneous
                  amenorrhea without an alternative medical cause and FSH levels in the
                  postmenopausal range for the laboratory involved)

               -  Males: Surgically sterile, abstinent or if engaged in sexual relations with women
                  of childbearing potential, patient is utilizing an acceptable contraceptive
                  method during and for 5 months after the last dose of ISIS 463588 or placebo
                  (Study Drug)

          3. Body Mass Index (BMI) between 30.0 and 40.0 kg/m2, inclusive

          4. Patients who are willing to comply with all scheduled visits, treatment plans,
             laboratory tests and other study procedures

          5. Agree to abstain from alcoholic beverages for at least 48 hours prior to clinic visits

          6. Agree to maintain current diet and exercise regimen from Screening until End-of-Study

        Exclusion Criteria:

          1. Clinically significant abnormalities in medical history (e.g., previous acute coronary
             syndrome within 6 months of Screening, major surgery within 3 months of Screening) or
             physical examination

          2. Positive test for HIV, hepatitis B or C at Screening

          3. Hypothyroidism or Hyperthyroidism

          4. Weight change &gt; 5% in the 3 months prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Energy Expenditure</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

